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ANRIL: A lncRNA at the CDKN2A/B
Locus With Roles in Cancer and
Metabolic Disease
Yahui Kong, Chih-Heng Hsieh and Laura C. Alonso*
Department of Medicine, Diabetes Center of Excellence, University of Massachusetts Medical School, Worcester, MA,
United States
The CDKN2A/B genomic locus is associated with risk of human cancers and metabolic
disease. Although the locus contains several important protein-coding genes, studies
suggest disease roles for a lesser-known antisense lncRNA encoded at this locus, called
ANRIL. ANRIL is a complex gene containing at least 21 exons in simians, with many
reported linear and circular isoforms. Like other genes, abundance of ANRIL is regulated
by epigenetics, classic transcription regulation, splicing, and post-transcriptional
influences such as RNA stability and microRNAs. Known molecular functions of
ANRIL include in cis and in trans gene regulation through chromatin modification
complexes, and influence over microRNA signaling networks. Polymorphisms at the
ANRIL gene are linked to risk for many different cancers, as well as risk of atherosclerotic
cardiovascular disease, bone mass, obesity and type 2 diabetes. A broad array
of variable reported impacts of polymorphisms on ANRIL abundance, splicing and
function suggests that ANRIL has cell-type and context-dependent regulation and
actions. In cancer cells, ANRIL gain of function increases proliferation, metastasis, cell
survival and epithelial-mesenchymal transformation, whereas ANRIL loss of function
decreases tumor size and growth, invasion and metastasis, and increases apoptosis and
senescence. In metabolic disease, polymorphisms at the ANRIL gene are linked to risk
of type 2 diabetes, coronary artery disease, coronary artery calcium score, myocardial
infarction, and stroke. Intriguingly, with the exception of one polymorphism in exon 2 of
ANRIL, the single nucleotide polymorphisms (SNPs) associated with atherosclerosis and
diabetes are non-overlapping. Evidence suggests that ANRIL gain of function increases
atherosclerosis; in diabetes, a risk-SNP reduced the pancreatic beta cell proliferation
index. Studies are limited by the uncertain relevance of rodent models to ANRIL studies,
since most ANRIL exons do not exist in mouse. Diverse cell-type-dependent results
suggest it is necessary to perform studies in the relevant primary human tissue for each
disease. Much remains to be learned about the biology of ANRIL in human health and
disease; this research area may lead to insight into disease mechanisms and therapeutic
approaches.
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INTRODUCTION
The discovery of functional noncoding RNAs has opened a
kaleidoscopic world of unanticipated mechanisms extending
far beyond the DNA-RNA-protein paradigm; noncoding RNAs
may in fact outnumber coding RNAs (1). Long noncoding
RNAs (lncRNAs) have been discovered throughout the genome;
scientists are working to explore their functions in health and
disease. The ANRIL lncRNA was first identified in a melanoma
kindred with a large (403 kb) deletion at the CDKN2A/B locus
(2). ANRIL has attracted broad attention because it is located
at a genomic hotspot for disease heritability, the CDKN2A/B
locus. Although protein coding genes at this locus have important
well-studied roles in cell cycle regulation, data suggest that some
locus disease-associated single nucleotide polymorphisms (SNPs)
act through effects on ANRIL itself. Intriguingly, studies suggest
ANRIL not only impacts the biology of cancer, but also has cell-
type-specific roles in metabolic disease. Although ANRIL has
been reviewed in the past (3, 4), knowledge has exponentially
increased in recent years. Here we review advances in ANRIL
SNPs, gene regulation, cell biology, and disease roles of ANRIL.
THE CDKN2A/B LOCUS
ANRIL, or CDKN2B-AS1, is located at the human CDKN2A/B
locus at 9p21.3. This gene cluster, extending over a nearly 350 kb
genomic region housed within a single topologically associated
domain (TAD) (5), contains three protein coding genes and,
antisense to them, the ANRIL lncRNA (Figure 1). The protein
coding genes include S-methyl-5
′
-thioadenosine phosphorylase
(MTAP), CDKN2A, which encodes splice variants p16INK4A and
p14ARF, and CDKN2B, which encodes p15INK4B (9, 10). MTAP
lies at one end of the locus, 192 kb telomeric to the 5
′
start of
ANRIL. At the centromeric end of the locus, the ANRIL gene
contains 19–21 reported exons over a 126 kb region. CDKN2A
lies between MTAP and ANRIL, near the first exon of ANRIL;
CDKN2B is located within the first intron of ANRIL, in an
antisense direction. The proteins encoded by CDKN2A and
CDKN2B are tumor suppressors with well-established roles in cell
proliferation, apoptosis, senescence and aging (11, 12). p16INK4A
and p15INK4B are cyclin dependent kinase (CDK) inhibitors,
inhibiting retinoblastoma phosphorylation by CDK4/6. The
p14ARF protein, a splice variant of CDKN2A which due to
a frame shift has no amino acid homology to the principal
other CDKN2A splice variant, p16INK4A, modulates p53 activity.
ANRIL is transcribed by RNA polymerase II and spliced into
multiple linear and circular isoforms in a tissue-specific manner.
In general, ANRIL roles, explored in detail below, include gene
regulation in cis and in trans through interaction with polycomb
Abbreviations: CAD, coronary artery disease; CAC, coronary artery calcium;
CDK, cyclin dependent kinase; circANRIL, circular ANRIL; circRNA, circular
RNA; GWAS, genome-wide association study; lncRNA, long noncoding RNA;
miRNA,microRNA;MI, myocardial infarction; MTAP, S-methyl-5
′
-thioadenosine
phosphorylase; PBMC, peripheral blood mononuclear cell; PBTL, peripheral
blood T-lymphocytes; PRC, polycomb repressive complex; SNP, single nucleotide
polymorphism; VSMC, vascular smooth muscle cells.
repressive complex (PRC) histone modifiers, as well as RNA-
RNA interactions such as microRNA (miRNA) sponge activity
(3, 13). Known biological impact of ANRIL activities include
modulation of proliferation, apoptosis and cellular adhesion
pathways (14).
EVOLUTION OF THE ANRIL GENE
The evolutionary development of the human ANRIL gene has
been studied by comparative analysis of the genomes of 27
organisms including non-mammalian vertebrates, non-placental
mammals, non-primate placental mammals, and primates (15).
ANRIL originated in ancestors of the Eutherian (placental)
mammalian clade. Initially the gene contained only a few exons;
over time, ANRIL underwent clade-specific evolution, adding
exons in many mammals but losing exons in rodents. The full 21
exon gene is present only in simians. ANRIL genes contain many
repeat elements, both intronic, and exonic; evidence suggests
that transposon activity has mediated many of the observed
evolutionary changes in exon presence or absence, location,
sequence, conservation, and structure, as well as introduction of
splice sites (15).
EarlyANRIL variants were likely not transcribed or functional
(15). One hallmark of functional RNAs is splice signals at
intron/exon boundaries. In simians, 191 intron/exon boundaries
contained canonical splice signals, while 20 did not. In lower
mammals, however, only about half of intron/exon junctions
contained identifiable splice signals (15). This finding suggests
that as ANRIL gained exons, and exon sequences became more
conserved across species, it also increased the number of splice
signals and gained functionality. Taken together, data suggest that
ANRILmay be functional only in simians, and that functionality
may have been introduced by transposon activity (15).
ANRIL ISOFORMS AND STRUCTURE
With at least 21 exons (new exons discovered as recently as 2017
(7)), the ANRIL gene can potentially generate a large number of
splice variants. In fact, many ANRIL isoforms have been reported
(Figure 1) (16). Exon numbering has changed over time as new
exons were discovered. Studies observe multiple isoforms in any
given cell type, mostly at low abundance. A different range of
isoforms may be identified from one cell type to another, but
tissue-dependent isoform expression in primary cells or tissues
has not yet been comprehensively quantified using the same
reagents and techniques. Intriguingly, many studies have now
identified both linear and circular ANRIL isoforms (6–8). The
longest open reading frame identified in any ANRIL variant is 86
codons, supporting the concept that functionality of this gene is
through RNA activity (16).
Linear and Circular Isoforms
Many conventional linear polyadenylated ANRIL isoforms are
detected in different cell types. Circular ANRIL (circANRIL)
isoforms, without polyadenylation, have also been described.
Circular RNAs, which are formed by “back-splicing” in which
a downstream splice donor site is joined to an upstream splice
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FIGURE 1 | CDKN2A/B locus and ANRIL isoforms. (A) At the CDKN2A/B
locus, the ANRIL lncRNA is antisense to the protein coding genes. The
p15INK4B gene is contained within intron 1 of ANRIL. (B) To date, ANRIL has
21 reported exons. (C,D) Numerous linear (C) and circular (D) exons have
been reported. Due to the discovery of additional exons, distal exons in some
circular isoforms have been renumbered based on the current 21 reported
exons. *Exons 15-16 refer to exons 14-15 in Holdt et al. (6). **Exon 16 refers
to exon 14 in Sarkar et al. (7) and Burd et al. (8).
acceptor site, were discovered in 2012 to be a broadly occurring
phenomenon across developmental stages and tissues, arising
from at least 14% of human transcribed genes (17, 18). CircRNAs
enjoy distinct properties from linear RNAs, including, in general,
enhanced stability and longevity, cytoplasmic localization, and
lack of translation (although if an IRES is engineered, circRNAs
can support translation) (19). Traditional PCR using antisense-
oriented primers cannot distinguish between linear and circular
isoforms; other methodology, such as PCR using “outward-
facing” primers directed away from each other, detection of
specific exon-exon junctions, or protection from RNAse R
digestion can quantify circular RNAs.
Careful examination of melanoma cell lines showed that
the abundance of individual ANRIL exons is non-uniform,
supporting the presence of different isoforms (7). In both
transformed cell lines and in human brain derived cells,
abundance of ANRIL exons was lower than exons from
locus protein-coding genes CDKN2A and CDKN2B (8). Linear
isoforms tend to include proximal exons (1-2), whereas isoforms
with only central exons (4-16) are more likely to be circular (8).
In melanoma cells, proximal exons (exon 1 and exon 5-6) were
more highly expressed than distal exons. This suggests that short
isoforms of ANRIL, which tend to include proximal exons, are
more abundant than longer isoforms in this cell type (7). In
human peripheral blood mononuclear cells and a monocyte cell
line, four major groups of ANRIL transcripts were found, all with
common proximal exons including exons 1, 5, and 6 but with
different distal exons, of various lengths (8). Multiple circular
ANRIL isoforms have been detected. A circANRIL isoform with
an exon 14-5 head-to-tail junction was reported to be the
predominant form in both an immortalized fibroblast cell line (8)
and in amajority of melanoma cell lines (7). Other non-canonical
back-spliced junctions observed in melanoma samples included
exon 14-5, 7-4, 10-5, and 14-4 (7). The exons most commonly
observed in circANRIL in melanoma cells were 4, 5, 6, 7, 10, 13,
and 14; in varied human cell types, the majority of circANRIL
species were exon 5-6-7 containing (6). ANRIL exons 1, 2, 3,
8, 9, 11, and 12 were rarely included in circular RNA products
(8). In melanoma lines, no correlation was observed between
abundance of linear and circANRIL (7). However, circANRIL
expression was inversely correlated with linearANRIL expression
in peripheral blood mononuclear cells in a cardiovascular cohort
(6). CircANRIL was found to be resistant to RNAse R digestion
compared with linear ANRIL, and an actinomycin D time course
confirmed enhanced stability of the 14-5 circANRIL isoform
compared with linear isoforms (7, 8).
Secondary Structure
Structure and function of lncRNAs is of high interest in
the scientific community, given the increasing recognition of
lncRNA roles in cancer and the normal biology of higher
organisms. As such, prediction of lncRNA structures is an
important computational challenge. One approach is to identify
structural elements through comparison of related lncRNAs. The
MONSTER tool was used to compare ANRIL to two lncRNAs
with similar biological function: HOTAIR and COLDAIR (20).
MONSTER identifies sequence-predicted secondary structure,
such as regions likely to be single stranded RNA, double
stranded RNA, hairpin loops, interior loops and bulges.
Comparing predictions of two lncRNAs with similar functions
is proposed as a mechanism to identify structural motifs.
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When HOTAIR, COLDAIR, and ANRIL were compared, several
common structures were identified, putative structural motifs
related to their common function in epigenetic regulation,
which could lead to a molecular understanding of mechanism
of action in future studies (20). Another study identified
the region of ANRIL that interacts with CBX7, a polycomb
repressor component; secondary structure analysis revealed
hairpin structural motifs with significant binding affinity to
CBX7. Fluorescence anisotropy suggested a ternary complex
between a particular loop of ANRIL, CBX7 and a H3K27me3
methylated histone peptide (21).
Cellular Localization
RNA localization impacts function. In melanoma cells, linear
ANRIL species containing proximal (exon 1) and distal
(exons 13b, 19) exons were predominantly found in the
nucleus. However, middle exons (exons 5, 6, and 7), which
are found in both linear and circANRIL, were observed
in cytoplasmic fractions, suggesting that circANRIL species
may be predominantly cytoplasmic (7). Nuclear localization
suggests linear isoforms may be responsible for the known
ANRIL function of regulating gene transcription via chromatin
modulation (see below). Conversely, cytoplasmic localization
suggests circANRIL forms may participate in post-transcriptional
functions. In gastric (22), prostate (21), and urothelial (23)
cancer cells, ANRIL was predominantly nuclear. In a beautiful
high-resolution analysis of single-molecule lncRNA localization,
ANRIL was found to be mostly localized to cell nuclei, in one
or several bright foci. Like other lncRNAs analyzed, ANRIL
nuclei foci were lost in mitotic cells (24). Physiological stimuli
that change ANRIL localization may provide clues as to ANRIL
functions. Intriguingly, in a retinal cell line ANRIL isoforms were
observed by fluorescence in situ hybridization to localize to the
peri-nuclear cytoplasmic space. ANRIL abundance was induced
by glucose, but ANRIL localization did not change with high
glucose exposure (25). On the other hand, a study in HUVEC
cells, using primers predicted to detect both linear and circular
isoforms, found ANRIL to be mostly nuclear; nuclear ANRIL was
increased after exposure to TNF-α (26). At least one study has
used ANRIL as a nuclear positive control to test localization of
other transcripts (27). Future cell type specific studies of ANRIL
localization under basal, stimulated, and stress conditions may
lead to clues as to ANRIL roles in tissue health and disease.
REGULATION OF ANRIL ABUNDANCE
Abundance of ANRIL species is determined by promoter
transcriptional activity, splicing decisions, and RNA stability
(Figure 2). Like other genes, ANRIL promoter activity is
influenced by epigenetic control and transcription factor
occupancy. Intriguingly, epidemiological findings suggest that
epigenetic regulation of ANRIL, through promoter methylation,
has important long-lasting consequences for tissue function (29–
31). As such, ANRIL regulation is one mediator of the impact of
early life environmental signals on adult human health.
ANRIL Promoter Methylation
Epidemiological and experimental findings demonstrate that
methylation of theANRIL promoter region regulatesANRIL gene
expression and has functional importance. The first exons of
ANRIL and p14ARF are separated by only 300 bp, in head-to-
head antisense orientation; the intergenic region between them
is a bidirectional promoter (4, 32, 33). In silico analysis of
ENCODE ChromHMM data (34) revealed that this region is
enriched for both promoter and enhancer activity, and DNAse
I hypersensitivity, across multiple cell types, suggesting this is
a regulatory region. This region is bound by CTCF, usually
considered to be a transcriptional repressor, insulating promoters
from enhancer activity. Oddly, CTCF binding at the ANRIL
promoter was associated with active-chromatin mark histone
H3K4 trimethylation (35). CTCF binding, and ANRIL and
p14ARF expression, were inhibited by methylation of local CpG
islands and increased by demethylation. Knockdown of CTCF
prevented the demethylation-induced expression of ANRIL
and p14ARF, confirming that CTCF is a methylation-sensitive
positive regulator of ANRIL promoter activity (35).
Additional evidence supports the functional importance of
CpG sites for ANRIL promoter activity, locus gene expression
and transcription factor binding. Mutagenesis of the CpG sites
affects both ANRIL and p14ARF promoter activity (29, 30).
Methylation status of several CpG differentially methylated
regions at ANRIL in umbilical cord tissues was positively
associated with abundance of linear but not circular ANRIL,
but inversely associated with p14ARF and p16INK4a expression
(29). CpG methylation also affects other transcription factors
binding at the ANRIL promoter to regulate downstream gene
expression, such as interferon gamma, SMAD3/4 and ERα (29,
30). Methylation status of CpG islands around the p16INK4A
transcription start site was also shown to coordinate transcription
of ANRIL and p16INK4A in human cells (36). Given the
multiple protein complexes binding across different CpG sites,
and variable quantitative impact of individual CpG region
mutagenesis on ANRIL isoforms and locus gene expression,
regulation appears to be complex.
Transcription Factors Regulate ANRIL
Production
ANRIL expression is influenced by cellular processes such as
genotoxic stress, tumorigenesis, senescence, and inflammation.
Activity at the bidirectional promoter region upstream of both
ANRIL and p14ARF genes is influenced by the critical cell
cycle regulator E2F1 (32, 33). In response to the genotoxic
stress of DNA damage, E2F1 transcriptionally activates ANRIL
in an ATM-dependent manner (33, 37). In this case, ANRIL
is thought to promote cell growth by suppressing locus INK-
family inhibitors after DNA repair is complete, allowing re-
entry into cell cycling (33). The ANRIL promoter was also
responsive to E2F1 in cancer cells (32). In addition to E2F1,
several known potent oncogenes regulate ANRIL expression
in various cancers. In lung cancer, c-MYC binds to an E-box
in the ANRIL promoter and induces ANRIL expression (38).
In nasopharyngeal carcinoma, transcription factor SOX2 was
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FIGURE 2 | Summary of regulation and functions of the ANRIL lncRNA. (Left) Some of the known mechanisms by which ANRIL abundance is regulated, at the
transcriptional and post-transcriptional levels. On the (Right), a selection of known ANRIL cellular functions are depicted. We apologize for observations not included
in this summary image. The ANRIL structural prediction in the center is of a common long-isoform of ANRIL, and was generated from Gruber et al. (28).
shown to bind directly to the ANRIL promoter and activate
transcription of ANRIL and its downstream effector β-catenin
(39). In liver cancer, SP1 binds the ANRIL promoter and
positively regulatesANRIL transcription (40). On the other hand,
TET2, a tumor suppressor in human gastric cancer, binds to the
promoter region of ANRIL and regulates expression of ANRIL as
well as p16INK4a, p15INK4b, and p14ARF (41). Transcription
regulation of ANRIL is involved not only in cell DNA damage
and oncogenesis, but also in disparate processes such as cell
senescence and inflammation. In senescence, oncogenic Ras
was found to reduce expression of ANRIL (13, 21, 42). In
inflammation, STAT1 activates the ANRIL locus in vascular
endothelial cells has been reported; CAD-associated ANRIL SNP
rs10757278, located in a known downstream enhancer region,
disrupts the STAT1 binding site and modulates IFN-γ induced
ANRIL expression via stimulation (43). Intriguingly, the binding
of STAT1 at this enhancer exerts cell-type specific regulation
of ANRIL expression: repression in lymphoblastoid cells lines,
but activation in HUVEC cells (43). In sum, data support an
important role for cell-type specific transcriptional regulation of
theANRIL lncRNA in a range of cellular processes and outcomes.
Regulation of ANRIL Splicing
Cell type dependent variation in abundance of different ANRIL
isoforms suggests that splicing may be a point of regulation
(8, 44). Almost nothing is known aboutANRIL splicing decisions.
Disease-associated ANRIL gene polymorphisms have shed light
on this process. In lymphocytes, the coronary artery disease
(CAD) associated SNP rs10757278 (intron 12) correlates with
abundance of certain circular (14-5 and 4-6) and linear (exon 1-2,
but not 18-19, containing) isoforms (8). The rs10757278A allele
was found to inhibit skipping of exon 15, promoting circANRIL
species ending in exon 14 (8). Mechanisms regulating ANRIL
splicing require further study.
Post-Transcriptional Regulation
Determinants of ANRIL transcript longevity and stability remain
uncertain, but miRNAs can participate. ANRIL, downregulated
following Kaposi’s sarcoma associated herpesvirus (KSHV)
infection, contains multiple seed matches for KSHV miRNAs.
Forced miRNA expression decreased ANRIL abundance, and
miRNA pull-down experiments confirmed a direct interaction.
In addition, KSHV latency associated proteins vFLIP and
vCyclin also decreased ANRIL abundance, suggesting post-
transcriptional miRNA-dependent and independent regulation
(45).
FUNCTIONS OF THE ANRIL LNCRNA
Transcription Regulation via Chromatin
Modifying Complexes
Many studies show that ANRIL functions in cells to regulate
gene expression via chromatin modification. Acting in cis,
ANRIL interacts with both PRC-1 and−2 to mediate epigenetic
transcriptional repression of neighboring genes CDKN2A and
CDKN2B, through mechanisms involving histone modification
and chromatin remodeling (13, 21, 33). ANRIL interacts with
PRC1 component CBX7 to recruit PRC1 to the p14ARF
and p16INK4A loci, silencing the CDKN2A locus by H3K27-
trimethylation (21). At CDKN2B, ANRIL was shown to
recruit SUZ12, a subunit of the PRC2 (13). ANRIL also
interacts with PRC-associated protein YY1 (46). Intriguingly,
the structural conformation of the methyl-lysine binding pocket
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in the chromodomain of CBX7, which interacts with H3K27-
trimethylation to cause chromatin compaction, is influenced
by allosteric RNA-protein binding with ANRIL (47). However,
despite this well-documented repression of other locus genes
by ANRIL, a positive correlation between ANRIL (both short
and long isoforms), CDKN2A and CDKN2B RNA abundance
has been frequently reported, suggesting transcriptional co-
regulation of these genes predominates in many tissues (8, 10, 14,
16, 44, 48–51).
ANRIL also acts in a PRC1/2 dependent mechanism to
repress distant genes in trans (32, 46). Trans regulation by
ANRIL may be dependent on Alu motifs, which are found both
in ANRIL transcripts and in the promoters of ANRIL target
genes (46). This mechanism was shown to regulate the CARD8
gene in endothelial cells (52). Polycomb group proteins, which
are highly enriched near Alu motifs across the genome, are
recruited to target gene promoters upon ANRIL over-expression.
In support of this concept, silencing ANRIL impacts expression
of a large number of genes across the genome (14). Separate
from chromatin modification,ANRIL is reported to regulateWnt
signaling by binding to SOX2, increasing transcriptional activity
of the WNT/β-catenin pathway (39).
miRNA Abundance and Activity
ANRIL also influences gene expression via miRNA networks.
ANRIL regulates miRNAs both at the epigenetic level, through
regulation of miRNA transcription, and through direct binding
to miRNAs, acting as a miRNA “sponge.” In gastric cancer
cells, ANRIL epigenetically silences miR-99a/miR-449a through
a PRC2 mechanism (22). In general, expression of ANRIL and its
target miRNAs are negatively correlated in tissues and cell lines
(22, 53–57). ANRIL has been described as having pro-oncogenic
effects by sponging miRNAs (see below for more details). On the
other hand, circANRIL containing exons 5-6-7 was found to lack
miRNA sponge activity (6). Inhibition of miRNAs can reverse the
effects of ANRIL knockdown.
Cellular Outcomes of ANRIL Activity
ANRIL has broad impacts on cell biology, including influence
over proliferation, senescence, apoptosis, extracellular matrix
remodeling, and inflammation (14). In cancer, ANRIL-miRNA
interactions regulate networks of downstream targets of miRNAs,
promoting an oncogenic role for ANRIL in cell proliferation,
metastasis, invasion, radio-resistance, drug-induced cytotoxicity
and apoptosis, involving many different signaling pathways (22,
53–57). Specifically, repression of cell cycle inhibitors p14ARF,
p15INK4B, and p16INK4A increases proliferation, decreases
senescence, and contributes to the DNA damage response
(13, 21, 33). PRC-mediated epigenetic repression of Kruppel-
like factor 2 (KLF2) influences proliferation and apoptosis
(40, 58). Cooperation between ANRIL and PRC-associated YY1
increases TNF-alpha dependent inflammatory mediators (IL-6,
IL-8) throughNF-kB (26).ANRIL influences the cellular response
to oxidative stress through a miR-125a regulation of MCL-1
(59). Circular ANRIL species were found to regulate ribosome
biogenesis in vascular smooth muscle cells (6).
THE ANRIL GENE IS ASSOCIATED WITH
HUMAN DISEASE
A primary driver of interest in ANRIL is the large body of
genomic data linking theANRIL gene with risk of human disease.
Genome-wide association studies (GWAS) have identified many
disease-associated SNPs in or near the ANRIL gene (60).
The CDKN2A/B locus is remarkable for the large number of
associated diseases, ranging from aging and frailty to cancer
to metabolic disease. Perhaps surprisingly given the validated
importance of the products of the CDKN2A and CDKN2B genes
in cell biology, in some cases ANRIL expression shows stronger
phenotype association than protein-coding CDKN2A/B locus
genes (4, 48), linking ANRIL itself to a range of important human
diseases.
ANRIL SNPs and Disease Risk
Studies indicate that SNPs in the ANRIL gene can impact ANRIL
expression and function. The CDKN2A/B locus is associated with
risk of cancer, atherosclerotic disease, type 2 diabetes, stroke,
aneurysm, periodontitis, Alzheimer’s disease, aging, frailty,
glaucoma, endometriosis, multiple sclerosis, hypertension (10,
61). Reviewed here are only SNPs within or downstream of the
ANRIL gene; broader CDKN2A/B locus disease associations have
been reviewed previously (10, 62). Integrating information from
published observations and the NCBI linkage disequilibrium
database (63), we find that disease-associated SNPs in the ANRIL
gene that modulate locus gene expression fall into approximately
six groups (Table 1) defined loosely by linkage block and reported
effects. Exceptions outnumber the rules, however; for nearly all
groups there are reports of SNPs with different or even opposite
effects. Summarized here is a generalized synopsis of the majority
of reports. Group A SNPs, while located in ANRIL introns,
generally impact CDKN2A/B but not ANRIL biology (48, 50, 64).
All other SNP groups have reported impacts on ANRIL itself, but
reports often describe conflicting direction of change. Some SNPs
are reported to fall in enhancer regions (43, 49, 64) or to impact
ANRIL splicing (8) or secondary structure (69, 74). The data are
incomplete. A particular weakness of the field is that although
tissue-specific effects are likely to determine how polymorphisms
impact disease risk, in many cases the relevant primary tissue has
not been tested.
Disease-Associated SNPs May Influence
ANRIL Abundance
There is no consistent global pattern with respect to SNP
impact on ANRIL abundance. For most SNP groups, risk-SNPs
are reported that both increase and decrease ANRIL levels
in different studies. Variability may be related to differences
in technique used to detect ANRIL that favor one isoform
over others, cell type studied, acute and chronic biology and
genetic origin of the cellular material studied, and of course the
individual biology of each polymorphism. Most ANRIL SNPs fall
in large linkage blocks, which are variable among different human
genetic groups; in many cases the SNP tested may not be the
causative SNP in the linkage block, and published linkage blocks
may not apply to the material tested if not carefully matched by
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TABLE 1 | Disease associated SNPs in/near the ANRIL gene that modulate locus gene expression.
SNP
group
Location in
ANRIL
SNPs Diseases associated Cell type tested Impact References
A Intron 1 rs2811712
rs598664
rs3218018
rs3218005
Frailty, cancers, diabetes,
MI, CAC
Blood, leukocytes Altered CDKN2A and
CDKN2B expression, but no
change in ANRIL expression
or not reported
(14, 48, 50, 64, 65)
Intron 2 rs662463
B Intron 1 rs3217992
rs3218020
CAD, glaucoma, cancer Blood Risk SNPs decrease ANRIL
expression
(14, 48)
C Intron 1 rs1063192 CAD, glaucoma, stroke, MI,
diabetes, cancers
Blood, lympho-blastoid
cells, HUVEC, lymphocytes,
islets
Increase/decrease ANRIL
expression. Possible
enhancer. Disrupt miRNA
binding site. Reduce beta
cell proliferation index
(14, 48, 66–68)
Exon 2 rs564398
Intron 2 rs7865618
D Intron 1 rs7044859
rs496892
Cancers, CAD, Stroke, MI,
CAC, glaucoma, cancers
Blood, PBMC,
lymphoblastoid cells,
HUVEC, leukocytes
Exonic SNPs change
predicted ANRIL free energy
calculation, may impact
secondary structure. Most
intronic SNPs decrease
ANRIL expression; possible
predicted enhancers
(4, 14, 43, 48, 50,
69, 70)
Exon 2 rs10965215
Intron 3 rs2151280
Exon 6 rs10738605
Intron 6 rs944799
E Intron 13 rs10116277
rs6475606
rs10738607
rs10757274
CAD, stroke, intracranial
aneurysm, MI, endo-
metriosis, hypertension,
cancers
Blood, PBMC, PBTL,
VSMC, atherosclerotic
plaque, primary vascular
tissue, lympho-blastoid,
HUVEC
Isoform-specific ANRIL
up/downregulation.
Experimentally tested
enhancer regions.
rs10757278 may impact
ANRIL splicing, promoting
circANRIL production
(8, 14, 16, 43, 44,
48, 49, 51, 71–73)
Intron 14 rs10757278
Intron 18 rs2383206
rs2383207
Intron 19 rs1333045
Distal to exon
21
rs10811656
rs1333049
F Distal to exon
21
rs2383208
rs10811661
Type 2 diabetes Blood, islets Decrease/increase ANRIL
expression, Predicted
enhancer region
(48, 68)
Groups A–F are defined loosely based on linkage disequilibrium (defined as LD>0.8 in Caucasian population in LDHap) and by predicted or tested impact on ANRIL expression or
structure. Intron and exon numbers are based on 21 exons.
origin. It is entirely possible that all conflicting results are correct;
for example, a CAD risk-SNP could increase pro-proliferative
ANRIL isoforms in endothelial, macrophage or vascular smooth
muscle cells to drive atherosclerosis, whereas a diabetes risk-
SNP at the same position could decrease proliferative ANRIL
isoforms in beta cells to limit beta cell mass. The complexity of the
human system necessitates testing the relevant ANRIL isoforms
in the relevant cell type, preferably in primary cells, in tissue- and
disease-specific manner.
A comprehensive review of all SNP effects is beyond the
scope of this review. Some ANRIL located disease-associated
SNPs impact both ANRIL expression and CDKN2A/CDKN2B
expression (14, 48); others impact ANRIL but not CDKN2A or
CDKN2B (14, 48, 60), and still others impact CDKN2A/CDKN2B
but not ANRIL (48, 50, 64). Some SNPs are located within
predicted or proven enhancer regions (10, 43, 48, 49, 64, 75) or
miRNA binding sites (65, 66), providing possible mechanisms of
cell type specific gene regulation.
Disease-Associated SNPs May Influence
ANRIL Structure or Function
Beyond regulation ofANRIL transcription, polymorphisms could
impact ANRIL function by influencing relative abundance of
different isoforms through RNA splicing or stability, or through
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altering the secondary structure or interactions of any given
isoform. Several studies have identified ANRIL isoform-specific
effects (50, 53, 67, 71, 72); for example, four SNPs forming an
atherosclerosis risk haplotype were associated with increased
expression of some, but not all, ANRIL isoforms (44). SNPs may
influence the relative abundance of linear compared to circular
isoforms (8). Several SNPs are reported to impact ANRIL free
energy of folding, resulting in a predicted change in secondary
structure, with implications for function and stability (48, 69, 74).
ANRIL IN CANCER
ANRIL was initially identified in a kindred of familial melanoma-
neural system tumor with a germ-line deletion of the entire
CDKN2A/B locus (2). Although the CDKN2A/B locus is deleted
or silenced in approximately 40% of human cancers, related to
the tumor suppressive actions of CDKN2A and CDKN2B (76),
ANRIL itself has pro-oncogenic properties. ANRIL is implicated
in many malignancies, including cancers of the bladder (77),
ovary (78, 79), lung (38, 58, 80–82), liver (40, 54, 83), stomach
(22), breast (57, 84, 85), esophagus (86), nasopharyngeal cavity
(39, 87, 88), thyroid (89), bone (90), cervix (91), colon (92),
prostate (21, 56), glioma (55), and others (76). High tissue
abundance of ANRIL in cancers is associated with aggressive
clinicopathologic features such as high histological grade tumor
size, advanced tumor-node-metastasis stage, and poor overall
survival (22, 38, 40, 58, 78, 79, 83, 87, 89, 91–93). Certain
SNPs within the ANRIL gene are associated with ANRIL and
CDKN2A/B locus gene expression and clinical parameters (4, 48,
70, 94–96). ANRIL may be useful as a prognostic biomarker and
a therapeutic target for clinical cancer management.
Molecular Mechanisms of ANRIL in Cancer
Accumulating evidence suggests that ANRIL participates in
tumorigenesis by influencing cell proliferation, apoptosis and
metastasis. Depletion or overexpression of ANRIL changes
expression levels of many genes involved in proliferation, cellular
adhesion and apoptosis (14, 32, 46). ANRIL overexpression
promotes proliferation, migration, invasion, and epithelial-
mesenchymal transformation but inhibits cell apoptosis; ANRIL
loss-of-function represses tumor size and growth rate, cell
proliferation, migration, invasion, metastasis, and enhances
apoptosis and senescence (22, 38, 55, 56, 58, 77, 80, 81, 84,
89–92). Suppression of ANRIL is required for Ras-induced
senescence (13, 21, 42). High ANRIL levels are associated
with resistance to chemotherapy, and ANRIL knockdown may
promote chemosensitivity (37, 79, 88, 97–99). On the other hand,
ANRIL mediated anti-oncogenic effects of phospholipase D in
lung cancers (82).
ANRIL may promote carcinogenesis through a number
of mechanisms. Canonical ANRIL transcriptional mechanisms
may play a role, such as by in cis suppression of the
CDKN2A/CDKN2B tumor suppressor genes (80, 81, 100), or
through PRC-mediated in trans gene regulation (40, 58, 80).
ANRIL miRNA regulation has been implicated in cancers as
well, including mechanisms involving let-7a and miR-125a in
nasopharyngeal and oral carcinoma (56, 88, 101), miR-99a/miR-
449a in gastric cancer (22), miR-122-5p in hepatocellular
carcinoma (54), miR-186 in cervical cancer (91), and miR-199a
in breast cancer (57), miR-34a in glioma (55), and miR-323 in
pediatric medulloblastoma (102). Transcription factors affected
by ANRIL in cancers include KLF2 (40, 58), SMAD (56, 86,
89) and β-catenin. ANRIL interacts with signal transduction
pathways in cancers such as PI3K/AKT, p38 MAPK, TGF-β,
ATM-E2F1, and MTOR (33, 55, 56, 86, 89, 99, 103). ANRIL can
also drive cancer progression by increasing glucose uptake for
glycolysis (87), through lymphangiogenesis via LYVE-1, VEFG-
C, and VEGFR-3 (92), and through invasion and metastasis via
MET and MMP3 (78). An intriguing but mostly unexplored
phenomenon is breakpoint fusion transcripts including exons
from ANRIL fused with exons from MTAP, a neighboring
protein-coding gene, which were identified in 20% of screened
melanoma cell lines (104).
ANRIL IN METABOLIC DISEASE
In addition to cancer, genome-wide association studies have
repeatedly and confidently identified links between the genomic
region containing ANRIL and risk of developing cardiometabolic
disease, including type 2 diabetes and manifestations of
atherosclerosis such as CAD and stroke (10, 62). This locus
influences risk not only of classic type 2 (obesity-related)
diabetes, but also with related syndromes such as gestational
diabetes, transplant-associated diabetes, and cystic fibrosis
related diabetes, but not risk of type 1 (autoimmune) diabetes
(10). Although diabetes is a clinical risk factor for atherosclerosis,
the genetic influence for these conditions at the ANRIL locus
is mostly non-overlapping, with atherosclerosis SNPs located
throughout the ANRIL gene, and T2D SNPs located distal to the
last ANRIL exon (7). One exception is a SNP located in ANRIL
exon 2, rs564398, which is associated with both T2D and CAD
(105). Since CDKN2A/B locus genes are known for their roles
in cell cycle regulation and cancer, and not metabolism, many
questions remain as to how this locus impacts metabolic disease.
ANRIL and Atherosclerotic Disease
Since ANRIL locus SNPs influence risk of atherosclerosis, many
studies have now tested whether ANRIL gene expression is
related to atherosclerosis-associated diseases. In subjects with
angiographically confirmed CAD in the Leipzig heart study,
specific ANRIL isoforms were positively correlated with CAD
risk SNP haplotype in PBMCs, whole blood, and atherosclerotic
plaque tissue (44). In the Framingham heart study, ANRIL
SNPs were associated with multiple CAD-related outcomes, and
showed isoform-specific ANRIL correlation in leukocytes, with
short isoforms predicted to contribute to CAD pathogenesis
(50). CAD risk-SNPs may regulate the relative abundance of
linear and circular ANRIL isoforms (8). Intriguingly, abundance
of ANRIL in circulating plasma was positively correlated with
in-stent restenosis (53), but in PBMCs harvested at the time
of angioplasty/reperfusion, ANRIL levels were lower in subjects
with myocardial infarction, but higher in subjects with older
age, diabetes, hypertension. In this cohort, ANRIL levels in
PBMCs improvedmodel prediction of subsequent left ventricular
dysfunction (106). ANRIL promoter methylation may mediate
an epigenetic influence on future cardiac risk; higher CpG
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methylation at birth was associated with higher pulse wave
velocity, a marker for increased arterial stiffness indicating
greater cardiovascular risk, at 9 years of age (31).
Mechanisms by which ANRIL impacts atherosclerotic disease
remain debated. In aortic smooth muscle cells, knockdown of
ANRIL using siRNA targeting exon 1 or exon 19 revealed altered
gene expression networks impacting cell proliferation, apoptosis,
extracellular matrix, and inflammation (14). Atherogenic gene
expression networks were regulated by ANRIL via the Alu
mechanism, in which Alu motifs target ANRIL to particular
gene locations, recruiting PRC complexes and altering gene
methylation status (46). ANRIL may impact risk of ischemic
stroke by regulating the Caspase recruitment domain 8 (CARD8)
gene in endothelial cells (52). A known CAD-associated miRNA,
miR-92a, may mediate some ANRIL effects; ANRIL targets
GATA2, MAP1B, and ARG1 were found to require miR-92a,
placing this miRNA downstream of ANRIL for some atherogenic
effects (69). Finally, ANRIL is related to inflammation: ANRIL
is increased by pro-inflammatory factors NF-κ B and TNF-α
in endothelial cells, and ANRIL was found to bind directly to
the YY1 transcription factor to mediate TNF-a induction of
cytokines IL-6 and IL-8 (26).
ANRIL and Obesity, Bone Mass, and
Estrogen Signaling
Although GWAS studies do not suggest a link between
CDKN2A/B locus SNPs and obesity risk in adult populations,
intriguingly, ANRIL may be a genomic site of environmental
epigenetic influence on obesity. The ANRIL promoter contains
CpG methylation sites that are differentially regulated across
samples. In human tissues taken at birth, lower CpGmethylation
in infancy predicted higher fat mass at 6 years of age, as well as
increased bone size, mineralization and density (29, 30). ANRIL
promoter methylation was also negatively correlated with BMI in
contemporaneous samples of peripheral blood from adolescents
and in adipose tissue from adults (29). Methylation of these CpG
sites increased tissue abundance of ANRIL RNA, in a mechanism
that might include increased activity of an estrogen response
element. Functional studies in a liposarcoma cell line showed that
transcription factor binding to an adjacent ERE was enhanced by
methylation, and estradiol increased ANRIL expression (29).
ANRIL and Type 2 Diabetes
Multiple SNPs in different linkage blocks at the CDKN2A/B locus
are associated with T2D risk; evidence in human populations
suggests these SNPs impact pancreatic islet mass or function (10).
Despite the fact that the T2D risk SNPs are located in or near the
ANRIL gene, the field has largely assumed the effect was mediated
by the protein coding genes at the locus, due to extensive
published work implicating p16INK4A in the regulation of
beta cell mass (10). However, although studies have found no
association between CDKN2A/B T2D SNPs and transcript level
of p14ARF, p15INK4B, or p16INK4A in human islets (10, 107), an
age-dependent positive association was identified between distal
T2D risk-SNPs (group F in Table 1) and ANRIL expression (68).
On the other hand, a T2D risk-SNP in ANRIL exon 2 (group C
in Table 1) was associated with reduced ANRIL expression, again
with no change in p14ARF, p15INK4B, or p16INK4A expression
(14, 48); however, these studies were carried out in blood rather
than islets. In human islets, this exon 2 SNPwas shown to remove
a CpG methylation site; risk allele was associated with reduced
islet insulin content but no change in locus gene expression (108).
Risk allele at this SNP was associated with impaired beta cell
proliferation response to high glucose (68). In a study relevant
to diabetic retinopathy, high glucose exposure increased ANRIL
expression in human retinal epithelial cells (25). In ANRIL was
found to increase expression of VEGF, a critical element of the
neovascularization that is central to damage from retinopathy, via
a mechanism involving PRC2 and miR200b (25, 109).
SUMMARY
Studies suggest the ANRIL lncRNA influences risk of a number
of diseases, including many types of cancer as well as metabolic
disease. Current understanding of ANRIL biology indicates
the primary function of this lncRNA is to regulate gene
expression, both locally at CDKN2A/B as well as across the
genome, via mechanisms including chromatin modulation,
transcription factor binding, and miRNA regulation. Knowledge
concerning ANRIL function in cancers is more solid and
advanced than for metabolic tissues. Mechanisms by which
SNPs influence ANRIL abundance remain uncertain and require
more study; how DNA methylation regulates ANRIL in cancers
also will benefit from more study. Much remains to be
learned about the structural complexity of ANRIL; how the
various identified linear and circular isoforms impact tissue
biology to modulate disease risk is mostly unknown. There
is an urgent need for deeper understanding of how ANRIL
isoforms modulate cellular function in human organs and
tissues, and to explore the differing roles of ANRIL in cancer
and metabolic disease. Given the advent of RNA therapeutics,
and the broad disease relevance of ANRIL, it is possible
that these studies may lead to future disease prevention and
treatment.
AUTHOR CONTRIBUTIONS
YK, C-HH, and LA wrote and revised the manuscript.
FUNDING
This work was supported by NIH/NIDDK: R01DK114686
and NIH/NIDDK DK095140 (LA), the American Diabetes
Association grant #1-18-IBS-233 (LA) in collaboration with the
Order of the Amaranth, and the George F. and Sybil H. Fuller
Foundation.
ACKNOWLEDGMENTS
We would like to thank the Beta Cell Biology Group at
the University of Massachusetts Medical School for helpful
discussions.
Frontiers in Endocrinology | www.frontiersin.org 9 July 2018 | Volume 9 | Article 405
Kong et al. ANRIL in Cancer and Metabolism
REFERENCES
1. Villegas VE, Zaphiropoulos PG. Neighboring gene regulation by
antisense long non-coding RNAs. Int J Mol Sci. (2015) 16:3251–66.
doi: 10.3390/ijms16023251
2. Pasmant E, Laurendeau I, Héron D, Vidaud M, Vidaud D, Bièche I.
Characterization of a germ-line deletion, including the entire INK4/ARF
locus, in a melanoma-neural system tumor family: identification of
ANRIL, an antisense noncoding RNA whose expression coclusters
with ARF. Cancer Res. (2007) 67:3963–9. doi: 10.1158/0008-5472.CAN-
06-2004
3. Congrains A, Kamide K, Ohishi M, Rakugi H. ANRIL: molecular
mechanisms and implications in human health. Int J Mol Sci (2013) 14:1278–
92. doi: 10.3390/ijms14011278
4. Pasmant E, Sabbagh A, VidaudM, Bièche I. ANRIL, a long, noncoding RNA,
is an unexpected major hotspot in GWAS. FASEB J Off Publ Fed Am Soc Exp
Biol. (2011) 25:444–8. doi: 10.1096/fj.10-172452
5. Rao SSP, Huntley MH, Durand NC, Stamenova EK, Bochkov ID,
Robinson JT, et al. A 3D map of the human genome at kilobase
resolution reveals principles of chromatin looping. Cell (2014) 159:1665–80.
doi: 10.1016/j.cell.2014.11.021
6. Holdt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W,
et al. Circular non-coding RNA ANRIL modulates ribosomal RNA
maturation and atherosclerosis in humans. Nat Commun. (2016) 7:12429.
doi: 10.1038/ncomms12429
7. Sarkar D, Oghabian A, Bodiyabadu PK, Joseph WR, Leung EY, Finlay GJ,
et al. Multiple isoforms of ANRIL in melanoma cells: structural complexity
suggests variations in processing. Int J Mol Sci. (2017) 18:E1378.
doi: 10.3390/ijms18071378
8. Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE. Expression
of linear and novel circular forms of an INK4/ARF-associated non-coding
RNA correlates with atherosclerosis risk. PLoS Genet (2010) 6:e1001233.
doi: 10.1371/journal.pgen.1001233
9. Holdt LM, Sass K, Gäbel G, Bergert H, Thiery J, Teupser D. Expression of
Chr9p21 genes CDKN2B (p15INK4b), CDKN2A (p16INK4a, p14ARF) and
MTAP in human atherosclerotic plaque. Atherosclerosis (2011) 214:264–70.
doi: 10.1016/j.atherosclerosis.2010.06.029
10. Kong Y, Sharma RB, Nwosu BU, Alonso LC. Islet biology, the CDKN2A/B
locus and type 2 diabetes risk. Diabetologia (2016) 59:1579–93.
doi: 10.1007/s00125-016-3967-7
11. Matheu A, Maraver A, Collado M, Garcia-Cao I, Cañamero M, Borras C,
et al. Anti-aging activity of the Ink4/Arf locus. Aging Cell (2009) 8:152–61.
doi: 10.1111/j.1474-9726.2009.00458.x
12. Cánepa ET, Scassa ME, Ceruti JM, Marazita MC, Carcagno AL, Sirkin
PF, et al. INK4 proteins, a family of mammalian CDK inhibitors
with novel biological functions. IUBMB Life (2007) 59:419–26.
doi: 10.1080/15216540701488358
13. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, et al.
Long non-coding RNA ANRIL is required for the PRC2 recruitment to and
silencing of p15 INK4B tumor suppressor gene.Oncogene (2011) 30:1956–62.
doi: 10.1038/onc.2010.568
14. Congrains A, Kamide K, Katsuya T, Yasuda O, Oguro R, Yamamoto K,
et al. CVD-associated non-coding RNA, ANRIL, modulates expression of
atherogenic pathways in VSMC. Biochem Biophys Res Commun (2012)
419:612–6. doi: 10.1016/j.bbrc.2012.02.050
15. He S, Gu W, Li Y, Zhu H. ANRIL/CDKN2B-AS shows two-stage clade-
specific evolution and becomes conserved after transposon insertions
in simians. BMC Evol Biol (2013) 13:247. doi: 10.1186/1471-2148-
13-247
16. Folkersen L, Kyriakou T, Goel A, Peden J, Mälarstig A, Paulsson-Berne G, et
al. Relationship between CAD risk genotype in the chromosome 9p21 locus
and gene expression. Identification of eight new ANRIL splice variants. PLoS
ONE (2009) 4:e7677. doi: 10.1371/journal.pone.0007677
17. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are
the predominant transcript isoform from hundreds of human genes in
diverse cell types. PLoS ONE (2012) 7:e30733. doi: 10.1371/journal.pone.003
0733
18. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular
RNAs are abundant, conserved, and associated with ALU repeats. RNA
(2013) 19:141–57. doi: 10.1261/rna.035667.112
19. Barrett SP, Salzman J. Circular RNAs: analysis, expression and potential
functions. Dev Camb Engl. (2016) 143:1838–47. doi: 10.1242/dev.128074
20. Fiscon G, Paci P, Iannello G. MONSTER v1.1: a tool to extract and
search for RNA non-branching structures. BMC Genomics (2015) 16:S1.
doi: 10.1186/1471-2164-16-S6-S1
21. Yap KL, Li S, Muñoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, et al.
Molecular Interplay of the noncoding RNA ANRIL and methylated
histone H3 lysine 27 by Polycomb CBX7 in transcriptional silencing
of INK4a. Mol Cell. (2010) 38:662–74. doi: 10.1016/j.molcel.2010.
03.021
22. Zhang E, Kong R, Yin D, You L, Sun M, Han L, Xu T, et al. Long noncoding
RNA ANRIL indicates a poor prognosis of gastric cancer and promotes
tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget
(2014) 5:2276–92. doi: 10.18632/oncotarget.1902
23. Hoffmann MJ, Dehn J, Droop J, Niegisch G, Niedworok C, Szarvas T,
Schulz WA. Truncated Isoforms of lncRNA ANRIL are overexpressed
in bladder cancer, but do not contribute to repression of INK4 tumor
suppressors. Non Coding RNA (2015) 1:266–84. doi: 10.3390/ncrna103
0266
24. Cabili MN, Dunagin MC, McClanahan PD, Biaesch A, Padovan-Merhar O,
Regev A, Rinn JL, Raj A. Localization and abundance analysis of human
lncRNAs at single-cell and single-molecule resolution. Genome Biol. (2015)
16:20. doi: 10.1186/s13059-015-0586-4
25. Thomas AA, Feng B, Chakrabarti S. ANRIL: a regulator of VEGF
in diabetic retinopathy. Invest Ophthalmol Vis Sci. (2017) 58:470–80.
doi: 10.1167/iovs.16-20569
26. Zhou X, Han X, Wittfeldt A, Sun J, Liu C, Wang X, et al. Long
non-coding RNA ANRIL regulates inflammatory responses as a
novel component of NF-κB pathway. RNA Biol. (2016) 13:98–108.
doi: 10.1080/15476286.2015.1122164
27. Cao S, Moss W, O’Grady T, Concha M, Strong MJ, Wang X, et al. New
noncoding lytic transcripts derived from the epstein-barr virus latency
origin of replication, oriP, are hyperedited, bind the paraspeckle protein,
NONO/p54nrb, and support viral lytic transcription. J Virol. (2015) 89:7120–
32. doi: 10.1128/JVI.00608-15
28. Gruber AR, Lorenz R, Bernhart SH, Neuböck R, Hofacker IL. The Vienna
RNAwebsuite.Nucleic Acids Res. (2008) 36:W70–4. doi: 10.1093/nar/gkn188
29. Lillycrop K, Murray R, Cheong C, Teh AL, Clarke-Harris R, Barton S, et al.
ANRIL promoter DNA methylation: a perinatal marker for later adiposity.
EBioMedicine (2017) 19:60–72. doi: 10.1016/j.ebiom.2017.03.037
30. Curtis EM, Murray R, Titcombe P, Cook E, Clarke-Harris R, Costello P, et
al. Perinatal DNAmethylation at CDKN2A is associated with offspring bone
mass: findings from the southampton Women’s survey. J Bone Miner Res Off
J Am Soc Bone Miner Res. (2017) 32:2030–40. doi: 10.1002/jbmr.3153
31. Murray R, Bryant J, Titcombe P, Barton SJ, Inskip H, Harvey NC, et
al. DNA methylation at birth within the promoter of ANRIL predicts
markers of cardiovascular risk at 9 years. Clin Epigenetics (2016) 8:90.
doi: 10.1186/s13148-016-0259-5
32. Sato K, Nakagawa H, Tajima A, Yoshida K, Inoue I. ANRIL is implicated in
the regulation of nucleus and potential transcriptional target of E2F1. Oncol
Rep. (2010) 24:701–7. doi: 10.3892/or_00000910
33. Wan G, Mathur R, Hu X, Liu Y, Zhang X, Peng G, et al. Long non-
coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling
pathway. Cell Signal. (2013) 25:1086–95. doi: 10.1016/j.cellsig.2013.02.006
34. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N,Ward LD, Epstein CB, et al.
Mapping and analysis of chromatin state dynamics in nine human cell types.
Nature (2011) 473:43–9. doi: 10.1038/nature09906
35. Rodriguez C, Borgel J, Court F, Cathala G, Forné T, Piette J. CTCF is a DNA
methylation-sensitive positive regulator of the INK/ARF locus. Biochem
Biophys Res Commun. (2010) 392:129–34. doi: 10.1016/j.bbrc.2009.12.159
36. Gan Y, Ma W, Wang X, Qiao J, Zhang B, Cui C, et al.
Coordinated transcription of ANRIL and P16 genes is silenced
by P16 DNA methylation. Chin J Cancer Res. (2018) 30:93–103.
doi: 10.21147/j.issn.1000-9604.2018.01.10
Frontiers in Endocrinology | www.frontiersin.org 10 July 2018 | Volume 9 | Article 405
Kong et al. ANRIL in Cancer and Metabolism
37. Özgür E, Mert U, Isin M, Okutan M, Dalay N, Gezer U. Differential
expression of long non-coding RNAs during genotoxic stress-induced
apoptosis in HeLa and MCF-7 cells. Clin Exp Med. (2013) 13:119–26.
doi: 10.1007/s10238-012-0181-x
38. Lu Y, Zhou X, Xu L, Rong C, Shen C, Bian W. Long noncoding
RNA ANRIL could be transactivated by c-Myc and promote tumor
progression of non-small-cell lung cancer. OncoTargets Ther. (2016) 9:3077–
84. doi: 10.2147/OTT.S102658
39. Wu JH, Tang JM, Li J, Li XW. Upregulation of SOX2-activated lncRNA
ANRIL promotes nasopharyngeal carcinoma cell growth. Sci Rep. (2018)
8:3333. doi: 10.1038/s41598-018-21708-z
40. Huang M, Chen W, Qi F, Xia R, Sun M, Xu T, et al. Long non-coding
RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell
apoptosis by epigenetic silencing of KLF2. J Hematol Oncol. (2015) 8:50.
doi: 10.1186/s13045-015-0146-0
41. Deng W, Wang J, Zhang J, Cai J, Bai Z, Zhang Z. TET2 regulates LncRNA-
ANRIL expression and inhibits the growth of human gastric cancer cells.
IUBMB Life (2016) 68:355–64. doi: 10.1002/iub.1490
42. Kotake Y, Naemura M, Kitagawa K, Niida H, Tsunoda T, Shirasawa
S, et al. Oncogenic Ras influences the expression of multiple lncRNAs.
Cytotechnology (2016) 68:1591–6. doi: 10.1007/s10616-014-9834-9
43. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman
N, et al. 9p21 DNA variants associated with coronary artery disease
impair interferon-γ signalling response. Nature (2011) 470:264–68.
doi: 10.1038/nature09753
44. Holdt LM, Beutner F, Scholz M, Gielen S, Gäbel G, Bergert H,
et al. ANRIL expression is associated with atherosclerosis risk at
chromosome 9p21. Arterioscler Thromb Vasc Biol. (2010) 30:620–7.
doi: 10.1161/ATVBAHA.109.196832
45. Sethuraman S, Gay LA, Jain V, Haecker I, Renne R. microRNA
dependent and independent deregulation of long non-coding RNAs
by an oncogenic herpesvirus. PLoS Pathog (2017) 13:e1006508.
doi: 10.1371/journal.ppat.1006508
46. Holdt LM, Hoffmann S, Sass K, Langenberger D, Scholz M, Krohn K, et al.
Alu elements in ANRIL non-coding RNA at chromosome 9p21 modulate
atherogenic cell functions through trans-regulation of gene networks. PLoS
Genet. (2013) 9:e1003588. doi: 10.1371/journal.pgen.1003588
47. Ren C, Smith SG, Yap K, Li S, Li J, Mezei M, et al. Structure-
Guided Discovery of Selective Antagonists for the Chromodomain of
Polycomb Repressive Protein CBX7. ACS Med Chem Lett. (2016) 7:601–5.
doi: 10.1021/acsmedchemlett.6b00042
48. Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B.
Chromosome 9p21 SNPs associated with multiple disease phenotypes
correlate with ANRIL expression. PLoS Genet (2010) 6:e1000899.
doi: 10.1371/journal.pgen.1000899
49. Jarinova O, Stewart AFR, Roberts R, Wells G, Lau P, Naing T, et
al. Functional analysis of the chromosome 9p21.3 coronary artery
disease risk locus. Arterioscler Thromb Vasc Biol. (2009) 29:1671–7.
doi: 10.1161/ATVBAHA.109.189522
50. Johnson AD, Hwang SJ, Voorman A, Morrison A, Peloso GM, Hsu YH, et al.
Resequencing and clinical associations of the 9p21.3 region: a comprehensive
investigation in the Framingham heart study. Circulation (2013) 127:799–
810. doi: 10.1161/CIRCULATIONAHA.112.111559
51. Motterle A, Pu X, Wood H, Xiao Q, Gor S, Liang Ng F, et al. Functional
analyses of coronary artery disease associated variation on chromosome
9p21 in vascular smooth muscle cells. Hum Mol Genet. (2012) 21:4021–9.
doi: 10.1093/hmg/dds224
52. Bai Y, Nie S, Jiang G, Zhou Y, Zhou M, Zhao Y, et al. Regulation of
CARD8 expression by ANRIL and association of CARD8 single nucleotide
polymorphism rs2043211 (p.C10X) with ischemic stroke. Stroke (2014)
45:383–8. doi: 10.1161/STROKEAHA.113.003393
53. Wang F, Su X, Liu C,WuM, Li B. Prognostic value of plasma long noncoding
RNA ANRIL for in-stent restenosis. Med Sci Monit Int Med J Exp Clin Res.
(2017) 23:4733–9. doi: 10.12659/MSM.904352
54. Ma J, Li T, Han X, Yuan H. Knockdown of LncRNA ANRIL suppresses cell
proliferation, metastasis, and invasion via regulating miR-122-5p expression
in hepatocellular carcinoma. J Cancer Res Clin Oncol. (2018) 144:205–14.
doi: 10.1007/s00432-017-2543-y
55. Dong X, Jin Z, Chen Y, Xu H, Ma C, Hong X, et al. Knockdown of long
non-coding RNA ANRIL inhibits proliferation, migration, and invasion but
promotes apoptosis of human glioma cells by upregulation of miR-34a. J Cell
Biochem. (2018) 119:2708–18. doi: 10.1002/jcb.26437
56. Zhao B, Lu YL, Yang Y, Hu LB, Bai Y, Li RQ, et al. Overexpression of lncRNA
ANRIL promoted the proliferation and migration of prostate cancer cells via
regulating let-7a/TGF-β1/ Smad signaling pathway. Cancer Biomark Sect Dis
Markers (2018) 21:613–20. doi: 10.3233/CBM-170683
57. Xu ST, Xu JH, Zheng ZR, Zhao QQ, Zeng XS, Cheng SX, et al.
Long non-coding RNA ANRIL promotes carcinogenesis via sponging
miR-199a in triple-negative breast cancer. Biomed Pharmacother
Biomedecine Pharmacother. (2017) 96:14–21. doi: 10.1016/j.biopha.2017.
09.107
58. Nie F, Sun M, Yang J, Xie M, Xu T, Xia R, et al. Long noncoding RNA ANRIL
promotes non-small cell lung cancer cell proliferation and inhibits apoptosis
by silencing KLF2 and P21 expression. Mol Cancer Ther. (2015) 14:268–77.
doi: 10.1158/1535-7163.MCT-14-0492
59. Li R, Yin F, Guo YY, Zhao KC, Ruan Q, Qi YM. Knockdown of ANRIL
aggravates H2O2-induced injury in PC-12 cells by targeting microRNA-
125a. Biomed Pharmacother Biomedecine Pharmacother. (2017) 92:952–61.
doi: 10.1016/j.biopha.2017.05.122
60. Broadbent HM, Peden JF, Lorkowski S, Goel A, Ongen H, Green F, et al.
Susceptibility to coronary artery disease and diabetes is encoded by distinct,
tightly linked SNPs in the ANRIL locus on chromosome 9p.HumMol Genet.
(2008) 17:806–14. doi: 10.1093/hmg/ddm352
61. Rezazadeh M, Gharesouran J, Moradi M, Noroozi R, Omrani MD,
Taheri M, et al. Association study of ANRIL genetic variants and
multiple sclerosis. J Mol Neurosci. (2018) 65:54–9 doi: 10.1007/s12031-018-
1069-3
62. Hannou SA, Wouters K, Paumelle R, Staels B. Functional genomics of
the CDKN2A/B locus in cardiovascular and metabolic disease: what have
we learned from GWASs? Trends Endocrinol Metab. (2015) 26:176–84.
doi: 10.1016/j.tem.2015.01.008
63. Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal
variants, cell types, regulators and target genes for human complex traits
and disease. Nucleic Acids Res. (2016) 44:D877–81. doi: 10.1093/nar/gk
v1340
64. Hungate EA, Vora SR, Gamazon ER, Moriyama T, Best T, Hulur I, et al.
A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell
precursor acute lymphoblastic leukaemia aetiology. Nat Commun. (2016)
7:10635. doi: 10.1038/ncomms10635
65. Gong J, Liu C, Liu W, Wu Y, Ma Z, Chen H, et al. An update of miRNASNP
database for better SNP selection by GWAS data, miRNA expression and
online tools. Database (2015) 2015:bav029. doi: 10.1093/database/
bav029
66. Wang X, Li W, Ma L, Gao J, Liu J, Ping F, et al. Association study
of the miRNA-binding site polymorphisms of CDKN2A/B genes with
gestational diabetes mellitus susceptibility. Acta Diabetol. (2015) 52:951–8.
doi: 10.1007/s00592-015-0768-2
67. Zhao W, Smith JA, Mao G, Fornage M, Peyser PA, Sun YV, et al. The
cis and trans effects of the risk variants of coronary artery disease in the
Chr9p21 region. BMC Med Genomics (2015) 8:21. doi: 10.1186/s12920-015-
0094-0
68. Kong Y, Sharma RB, Ly S, Stamateris RE, Jesdale WM, Alonso LC.
CDKN2A/B T2D genome-wide association study risk SNPs impact locus
gene expression and proliferation in human islets. Diabetes (2018) 67:872–
84. doi: 10.2337/db17-1055
69. Cheng M, An S, Li J. CDKN2B-AS may indirectly regulate coronary artery
disease-associated genes via targeting miR-92a. Gene (2017) 629:101–7.
doi: 10.1016/j.gene.2017.07.070
70. Poi MJ, Li J, Sborov DW, VanGundy Z, Cho YK, Lamprecht M, et
al. Polymorphism in ANRIL is associated with relapse in patients with
multiple myeloma after autologous stem cell transplant. Mol Carcinog.
(2017) 56:1722–32. doi: 10.1002/mc.22626
71. Zhuang J, Peng W, Li H, Wang W, Wei Y, Li W, et al. Methylation
of p15INK4b and expression of ANRIL on chromosome 9p21 are
associated with coronary artery disease. PLoS ONE (2012) 7:e47193.
doi: 10.1371/journal.pone.0047193
Frontiers in Endocrinology | www.frontiersin.org 11 July 2018 | Volume 9 | Article 405
Kong et al. ANRIL in Cancer and Metabolism
72. Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Mohlke KL, et
al. INK4/ARF transcript expression is associated with chromosome
9p21 variants linked to atherosclerosis. PLoS ONE (2009) 4:e5027.
doi: 10.1371/journal.pone.0005027
73. Zhang W, Chen Y, Liu P, Chen J, Song L, Tang Y, et al. Variants on
chromosome 9p21.3 correlated with ANRIL expression contribute to stroke
risk and recurrence in a large prospective stroke population. Stroke (2012)
43:14–21. doi: 10.1161/STROKEAHA.111.625442
74. Gong W, Peng J, Yin J, Li X, Zheng W, Xiao L, et al. Association between
well-characterized lung cancer lncRNA polymorphisms and platinum-based
chemotherapy toxicity in Chinese patients with lung cancer. Acta Pharmacol
Sin. (2017) 38:581–90. doi: 10.1038/aps.2016.164
75. Nakaoka H, Gurumurthy A, Hayano T, Ahmadloo S, Omer WH,
Yoshihara K, et al. Allelic Imbalance in Regulation of ANRIL through
chromatin interaction at 9p21 endometriosis risk locus. PLOS Genet. (2016)
12:e1005893. doi: 10.1371/journal.pgen.1005893
76. Tano K, Akimitsu N. Long non-coding RNAs in cancer progression. Front
Genet. (2012) 3:219. doi: 10.3389/fgene.2012.00219
77. Zhu H, Li X, Song Y, Zhang P, Xiao Y, Xing Y. Long non-coding
RNA ANRIL is up-regulated in bladder cancer and regulates bladder
cancer cell proliferation and apoptosis through the intrinsic pathway.
Biochem Biophys Res Commun. (2015) 467:223–8. doi: 10.1016/j.bbrc.2015.
10.002
78. Qiu JJ, Lin YY, Ding JX, Feng WW, Jin HY, Hua KQ. Long non-coding
RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in
serous ovarian cancer. Int J Oncol. (2015) 46:2497–505. doi: 10.3892/ijo.2015.
2943
79. Hu X, Bao J, Wang Z, Zhang Z, Gu P, Tao F, et al. The plasma
lncRNA acting as fingerprint in non-small-cell lung cancer. Tumour
Biol J Int Soc Oncodevelopmental Biol Med. (2016) 37:3497–504.
doi: 10.1007/s13277-015-4023-9
80. Naemura M, Murasaki C, Inoue Y, Okamoto H, Kotake Y. Long noncoding
RNA ANRIL regulates proliferation of non-small cell lung cancer and
cervical cancer cells. Anticancer Res. (2015) 35:5377–82.
81. Qiu J, Wang Y, Liu Y, Zhang Y, Ding J, Hua K. The long non-coding
RNA ANRIL promotes proliferation and cell cycle progression and inhibits
apoptosis and senescence in epithelial ovarian cancer. Oncotarget (2016)
7:32478–92. doi: 10.18632/oncotarget.8744
82. Kang YH, Kim D, Jin EJ. Down-regulation of phospholipase D stimulates
death of lung cancer cells involving up-regulation of the Long ncRNA
ANRIL. Anticancer Res. (2015) 35:2795–2803.
83. Hua L, Wang CY, Yao KH, Chen JT, Zhang JJ, Ma WL. High expression
of long non-coding RNA ANRIL is associated with poor prognosis in
hepatocellular carcinoma. Int J Clin Exp Pathol. (2015) 8:3076–82.
84. Liu M, Xing LQ, Liu YJ. A three-long noncoding RNA signature as
a diagnostic biomarker for differentiating between triple-negative and
non-triple-negative breast cancers. Medicine (2017) 96:e6222.
doi: 10.1097/MD.0000000000006222
85. Meseure D, Vacher S, Alsibai KD, Nicolas A, Chemlali W, Caly M,
et al. Expression of ANRIL-polycomb complexes-CDKN2A/B/ARF genes
in breast tumors: identification of a two-gene (EZH2/CBX7) signature
with independent prognostic value. Mol Cancer Res. (2016) 14:623–33.
doi: 10.1158/1541-7786.MCR-15-0418
86. Chen D, Zhang Z, Mao C, Zhou Y, Yu L, Yin Y, et al. ANRIL
inhibits p15(INK4b) through the TGFβ1 signaling pathway in human
esophageal squamous cell carcinoma. Cell Immunol. (2014) 289:91–6.
doi: 10.1016/j.cellimm.2014.03.015
87. Zou ZW, Ma C, Medoro L, Chen L, Wang B, Gupta R, et al. LncRNA
ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the
cancer progression via increasing proliferation, reprograming cell glucose
metabolism and inducing side-population stem-like cancer cells. Oncotarget
(2016) 7:61741–54. doi: 10.18632/oncotarget.11437
88. Wang Y, Cheng N, Luo J. Downregulation of lncRNA ANRIL
represses tumorigenicity and enhances cisplatin-induced cytotoxicity
via regulating microRNA let-7a in nasopharyngeal carcinoma. J Biochem
Mol Toxicol. (2017) 31:e21904 doi: 10.1002/jbt.21904
89. Zhao JJ, Hao S, Wang LL, Hu CY, Zhang S, Guo LJ, et al. Long non-coding
RNA ANRIL promotes the invasion and metastasis of thyroid cancer cells
through TGF-β/Smad signaling pathway. Oncotarget (2016) 7:57903–18.
doi: 10.18632/oncotarget.11087
90. Cheng S, Huang T, Li P, Zhang W, Wang Z, Chen Y. Long non-coding
RNA ANRIL promotes the proliferation, migration and invasion
of human osteosarcoma cells. Exp Ther Med. (2017) 14:5121–5.
doi: 10.3892/etm.2017.5123
91. Zhang JJ, Wang DD, Du CX, Wang Y. Long noncoding RNA ANRIL
promotes cervical cancer development by acting as a sponge of miR-186.
Oncol Res. (2017) 26:345–52. doi: 10.3727/096504017X14953948675449
92. Sun Z, Ou C, Ren W, Xie X, Li X, Li G. Downregulation of long non-
coding RNA ANRIL suppresses lymphangiogenesis and lymphatic
metastasis in colorectal cancer. Oncotarget (2016) 7:47536–55.
doi: 10.18632/oncotarget.9868
93. Wang H, Liu Y, Zhong J, Wu C, Zhong Y, Yang G, et al. Long
noncoding RNA ANRIL as a novel biomarker of lymph node metastasis and
prognosis in human cancer: a meta-analysis. Oncotarget (2018) 9:14608–18.
doi: 10.18632/oncotarget.21825
94. Stacey SN, Sulem P, Masson G, Gudjonsson SA, Thorleifsson G,
Jakobsdottir M, et al. New common variants affecting susceptibility
to basal cell carcinoma. Nat Genet. (2009) 41:909–14. doi: 10.1038/
ng.412
95. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E,
et al. Genome-wide association study identifies three loci associated
with melanoma risk. Nat Genet. (2009) 41:920–5. doi: 10.1038/
ng.411
96. Gu F, Pfeiffer RM, Bhattacharjee S, Han SS, Taylor PR, Berndt S, et al.
Common genetic variants in the 9p21 region and their associations with
multiple tumours. Br J Cancer (2013) 108:1378–86. doi: 10.1038/bjc.2013.7
97. Xu R, Mao Y, Chen K, He W, Shi W, Han Y. The long noncoding
RNA ANRIL acts as an oncogene and contributes to paclitaxel resistance
of lung adenocarcinoma A549 cells. Oncotarget (2017) 8:39177–84.
doi: 10.18632/oncotarget.16640
98. Lan WG, Xu DH, Xu C, Ding CL, Ning FL, Zhou YL, et al. Silencing of long
non-coding RNAANRIL inhibits the development of multidrug resistance in
gastric cancer cells. Oncol Rep. (2016) 36:263–70. doi: 10.3892/or.2016.4771
99. Zhang D, Ding L, Li Y, Ren J, Shi G, Wang Y, et al. Midkine derived from
cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation
of the expression of lncRNA ANRIL in tumour cells. Sci Rep. (2017) 7:16231.
doi: 10.1038/s41598-017-13431-y
100. Xu S, Wang H, Pan H, Shi Y, Li T, Ge S, et al. ANRIL lncRNA triggers
efficient therapeutic efficacy by reprogramming the aberrant INK4-hub
in melanoma. Cancer Lett. (2016) 381:41–8. doi: 10.1016/j.canlet.2016.
07.024
101. Chai L, Yuan Y, Chen C, Zhou J, Wu Y. The role of long non-coding
RNA ANRIL in the carcinogenesis of oral cancer by targeting miR-
125a. Biomed Pharmacother. (2018) 103:38–45. doi: 10.1016/j.biopha.2018.
01.105
102. Zhang H, Wang X, Chen X. Potential role of long non-coding RNA
ANRIL in pediatric medulloblastoma through promotion on proliferation
and migration by targeting miR-323. J Cell Biochem. (2017) 118:4735–44.
doi: 10.1002/jcb.26141
103. Yu G, Liu G, Yuan D, Dai J, Cui Y, Tang X. Long non-coding RNA
ANRIL is associated with a poor prognosis of osteosarcoma and promotes
tumorigenesis via PI3K/Akt pathway. J Bone Oncol. (2018) 11:51–5.
doi: 10.1016/j.jbo.2018.02.002
104. Xie H, Rachakonda PS, Heidenreich B, Nagore E, Sucker A, Hemminki K,
et al. Mapping of deletion breakpoints at the CDKN2A locus in melanoma:
detection of MTAP-ANRIL fusion transcripts. Oncotarget (2016) 7:16490–
504. doi: 10.18632/oncotarget.7503
105. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS,
Lango H, et al. Replication of genome-wide association signals in UK
samples reveals risk loci for type 2 diabetes. Science (2007) 316:1336–41.
doi: 10.1126/science.1142364
106. Vausort M, Wagner DR, Devaux Y. Long noncoding RNAs in
patients with acute myocardial infarction. Circ Res (2014) 115:668–77.
doi: 10.1161/CIRCRESAHA.115.303836
107. Taneera J, Lang S, Sharma A, Fadista J, Zhou Y, Ahlqvist E, et al. A
systems genetics approach identifies genes and pathways for type 2 diabetes
Frontiers in Endocrinology | www.frontiersin.org 12 July 2018 | Volume 9 | Article 405
Kong et al. ANRIL in Cancer and Metabolism
in human islets. Cell Metab. (2012) 16:122–34. doi: 10.1016/j.cmet.2012.
06.006
108. Dayeh TA, Olsson AH, Volkov P, Almgren P, Rönn T, Ling C. Identification
of CpG-SNPs associated with type 2 diabetes and differential DNA
methylation in human pancreatic islets. Diabetologia (2013) 56:1036–46.
doi: 10.1007/s00125-012-2815-7
109. Ruiz MA, Feng B, Chakrabarti S. Polycomb repressive complex
2 regulates MiR-200b in retinal endothelial cells: potential
relevance in diabetic retinopathy. PLoS ONE (2015) 10:e0123987.
doi: 10.1371/journal.pone.0123987
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Kong, Hsieh and Alonso. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Endocrinology | www.frontiersin.org 13 July 2018 | Volume 9 | Article 405
